Facility team in the of the UofL Health - Brown Cancer Center GMP Manufacturing Facility at the University of Louisville.…
P2B001 is a novel proprietary fixed-dose combination of extended-release (ER) formulations of low doses of pramipexole and rasagiline; both doses…
Recent research study demonstrates that the majority of clients experience reliable improvement in symptoms after just two months of treatmentVANCOUVER,…
Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics,…
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company…
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A…
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger,…
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- BVI, a diversified global ophthalmic device company, today announced certification for its…
EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs First-in-human study will…
TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies CHATHAM, N.J., Sept.…